A Phase 4 interventional study of TECNIS PureSee IOL (Model DEN00V/DET150) and TECNIS PureSee IOL (Model DEN00V/DET150) in Presbyopia Correction, Presbyopia and Dysphotopsia, sponsored by Dr. Daniel H. Chang, MD. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Dr. Daniel H. Chang, MD · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.
Among the 131 studies in Presbyopia with a site in United States, this one is the 64th largest by planned enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2026, is one of 8 in phase 4, and was the 131st registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:
Gordon Schanzlin New Vision · Sites in United States
Ages 40+ · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 18–40 · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 45–64
VIS, Inc. · Sites in United States
Ages 40+
Bausch & Lomb Incorporated · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 20 · Phase 4 8
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is above the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 75 across the 120 interventional studies, 46 across the 11 observational. Of the 113 that completed or were terminated, 84 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 131 have an industry lead sponsor. The 10 most frequent:
Dr. Daniel H. Chang, MD is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Dr. Daniel H. Chang, MD has 1 study filed under Presbyopia — fewer than ten, so there is no comparison to draw.
4 of the studies in Presbyopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT07638943Gordon Schanzlin New VisionRefitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses | 2027-01-31 |
| NCT07860567Dr. Daniel H. Chang, MDClinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match | 2027-03-01 |
| NCT06060041Bausch & Lomb IncorporatedIC-8 Apthera IOL New Enrollment Post Approval Study | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies in Presbyopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the binocular clinical endpoints of distance, intermediate, and near vision and patient reported outcomes utilizing mini-monovision versus mix-match approaches for the correction of presbyopia with intraocular lenses.
Presbyopia, defined as the age-related loss of accommodative amplitude, affects essentially all human beings beyond the age of 45 and impacts the ability of the eye to focus at near distances. Current intraocular lens (IOL) options for cataract patients who desire improved vision across a range of distances include full depth of field (DOFi) IOLs and extended depth of field (EDOF) IOLs. Patients implanted with full depth of field IOLs may sometimes experience dysphotopsias (e.g., glare and halos), particularly at night.
The goal with the correction of presbyopia is to maximize near visual range while minimizing the dysphotopsia profile. Bilateral implantation of extended depth of field lenses with a mini-monovision aim is one way to achieve this goal. EDOF lenses minimize the dysphotopsia profile and a near aim in the non-dominant eye will maximize the near visual range. Another option to achieve this goal is the mix-match approach with EDOF and a DOFi lens. The EDOF IOL minimizes the dysphotopsia profile while DOFi IOL maximizes the near visual range.
The hypothesis is that the mini-monovision and mix-match group will have equivalent uncorrected intermediate visual acuities. The mini-monovision group will have superior visual symptoms and the mix-match group will have superior uncorrected distance and near visual acuity, and spectacle independence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive bilateral TECNIS PureSee IOLs (Model DEN00V/DET150), with the non-dominant eye targeted for a "second minus" near aim to achieve mini-monovision.
Device: TECNIS PureSee IOL (Model DEN00V/DET150)
Participants will receive a TECNIS PureSee IOL (Model DEN00V/DET150) in their dominant eye and a TECNIS Odyssey IOL (Model DRN00V/DRT150) in their non-dominant eye.
Device: TECNIS PureSee IOL (Model DEN00V/DET150) · Device: TECNIS Odyssey IOL (Model DRN00V/DRT150)
Bilateral implantation of the TECNIS PureSee intraocular lens following standard phacoemulsification cataract surgery. The non-dominant eye is intentionally targeted for a "second minus" near focus strategy (mini-monovision).
Implantation of the TECNIS PureSee intraocular lens into the dominant eye following standard phacoemulsification cataract surgery.
Implantation of the TECNIS Odyssey intraocular lens into the non-dominant eye following standard phacoemulsification cataract surgery.
Binocular UCDVA
Binocular Uncorrected Distance Visual Acuity
Time frame: At 3-month postoperative study visit
Binocular UCIVA
Binocular Uncorrected Intermediate Visual Acuity
Time frame: At 3-month postoperative study visit
Binocular UCNVA
Binocular Uncorrected Near Visual Acuity
Time frame: At 3-month postoperative study visit
Patient Reported Outcomes PRVSQv2
Patient Reported Outcomes (as recorded by the PRVSQ2 questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.
Time frame: At 3-month postoperative study visit
Patient Reported Outcomes PRSIQv2
Patient Reported Outcomes (as recorded by the PRSIQ2 questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.
Time frame: At 3-month postoperative study visit.
Residual Refractive Error
Residual Refractive Error
Time frame: At 3-month postoperative study visit
Halometry
Dysphotopsias Measured by Clinical Halometry
Time frame: At 3-month postoperative study visit
Spectacle Use
Patient Reported Spectacle Use
Time frame: At 3-month postoperative study visit
Other Ocular/Visual Symptoms
Unsolicited visual or eye-related complaints volunteered by participants rather than specifically probed by the investigator. Serves as a secondary safety or tolerability measure to monitor unexpected sensory side effects. Quantified via non-leading, open-ended questioning during study visits or via non-directed adverse event logging
Time frame: At 3-month postoperative study visit
Patient Recommendation and Satisfaction
Patient Recommendation and Satisfaction (as recorded by the PQRS questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.
Time frame: At 3-month postoperative study visit
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Daniel H. Chang, MD